跳至主要内容
临床试验/NCT04370002
NCT04370002招募中不适用

Leveraging Artificial Intelligence for the Assessment of Severity of Depressive Symptoms

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年1月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
2
主要终点
The Hamilton Depression Rating Scale (HDRS) 17-items

研究概览

简要总结

This is a longitudinal study where individual with Major Depressive Disorder (MDD) will be monitored for 12 weeks. The study aims to develop an objective, sensor-based, algorithm able to detect the presence of depression as well as predict treatment response. Measurement-based treatment is considered optimal and the development of a valid passive, objective, behavioral and biological assessment of depressive symptoms that does not rely on clinician interviews will improve monitoring and ultimately improve treatment significantly.

详细描述

In this longitudinal study 100 individuals with Major Depressive Disorder (MDD) will be monitored for 12 weeks. Data will include self-report surveys, in-person assessments, physiological features derived by wearable devices and socialization and activity data derived by mobile applications. The study will utilize advanced statistical methods to integrate different sources of passive sensor-based behavioral and physiological data to develop models able to detect depression and predict treatment response.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (ages 18-75),
  • Able to read, understand, and provide written informed consent in English,
  • Meet criteria for a primary psychiatric diagnosis of current major depressive disorder
  • Hamilton Depression Rating Scale (HDRS) total score ≥ 18,
  • Must have measurable skin conductance/electrodermal activity (as assessed at the screening visit),
  • Must own a working smartphone and use it regularly,
  • Must own a windows PC (or tablet) or a Mac computer (or laptop),
  • Must have access to Internet service every day.
  • Must have started antidepressant medications, changed medication dosage, or started therapy within 3 weeks

排除标准

  • Active drug or alcohol use disorder in the past 3 months,
  • History of psychotic disorder,
  • History of mania or hypomania,
  • Epilepsy or history of Seizure Disorder (including PNES), narcolepsy, Alzheimer Disease, Parkinson's Disease, ALS, Severe TBI, Dementia, MS, Cerebral Palsy, and Neuralgia.
  • Untreated hypothyroidism,
  • Unstable medical disease,
  • Cognitive impairment that would impede adherence to study procedures,
  • Acute suicide or homicide risk,
  • Current treatment with electroconvulsive therapy, vagal nerve stimulation therapy, deep brain stimulation, transcranial magnetic stimulation therapy, or phototherapy,
  • Cannot comprehend or communicate in English,
  • Lack of working smartphone or lack of daily access to Internet service,
  • Inability to measure skin conductance/electrodermal activity (as assessed at the screening visit), and
  • Inability or unwilling to, at minimum, wear the physiological sensor (E4) wristbands, download monitoring apps, and fill out the surveys.
  • Participants with more than two treatment failures (more than two adequate trials of meds on the basis of ATRQ) in the current mood episode.

结局指标

主要结局

The Hamilton Depression Rating Scale (HDRS) 17-items

时间窗: Past week.

The HDRS-17 is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. Total score can range from 0 to 53.

次要结局

  • Patient Health Questionnaire 9 (PHQ-9)(Past 7 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Paola Pedrelli

Assistant Professor

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验